Patients’ adherence to drug therapy to control
chronic diseases is notoriously poor, particularly
when the disease is asymptomatic. Moreover,
self-reporting of adherence correlates very
poorly with reality. How can you improve this situation…
Management of Angle Closure in the Nanophthalmic Patient
h4CASE PRESENTATION/h4
A 48-year-old white woman presented to Credit Valley
Eyecare in Mississauga, Ontario, Canada, with nanophthalmos
and acute chronic angle-closure glaucoma in her
right eye. The latter was caused by a combination of
m…
The Cost-effective Use of Diagnostic Technologies
Primary open-angle glaucoma currently
affects at least 2.2 million
individuals over the age of 40 in
the United States.sup1/sup Considering
the disproportionate growth of the elderly
population, the incidence of glaucoma is
expected to r…
Learn to Ask Yourself the Essential Questions
emThe “Landmark Studies” column will focus on the main
findings of historic studies in glaucoma and how their results
should change physicians’ practices./em
h4WHAT IS A LANDMARK STUDY?/h4
A landmark study asks a compellin…
INDUSTRY NEWS AND INNOVAT IONS
h4Merck to Acquire Inspire
Pharmaceuticals, Inc./h4
Merck and Co., Inc. (Whitehouse Station, NJ), and Inspire
Pharmaceuticals, Inc. (Raleigh, NC), announced that they
have entered into a definitive agreement under which
Merck will acquire I…
Highlights of the AGS Annual Meeting
Every year, the AGS meeting features presentations of
the best in glaucoma research. This year, more than
600 registrants enjoyed 68 poster and 24 paper presentations
as well as a glaucoma surgery day, several
symposia, roundtables, workshops,…